Short Interest in Achilles Therapeutics plc (NASDAQ:ACHL) Drops By 25.1%

Achilles Therapeutics plc (NASDAQ:ACHL) was the recipient of a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 159,300 shares, a decline of 25.1% from the October 15th total of 212,600 shares. Currently, 0.4% of the company’s stock are short sold. Based on an average daily volume of 642,000 shares, the days-to-cover ratio is currently 0.2 days.

Achilles Therapeutics Price Performance

Shares of NASDAQ:ACHL opened at $1.05 on Friday. Achilles Therapeutics has a 1 year low of $0.63 and a 1 year high of $1.76. The company has a market cap of $43.14 million, a P/E ratio of -0.64 and a beta of 1.35. The stock’s fifty day moving average price is $0.96 and its 200-day moving average price is $0.87.

Achilles Therapeutics (NASDAQ:ACHL) last posted its earnings results on Wednesday, August 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.41). On average, sell-side analysts anticipate that Achilles Therapeutics will post -1.7 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Acadian Asset Management LLC bought a new position in Achilles Therapeutics in the first quarter valued at about $350,000. StemPoint Capital LP purchased a new stake in shares of Achilles Therapeutics during the 1st quarter valued at about $1,732,000. Ikarian Capital LLC bought a new position in shares of Achilles Therapeutics in the 1st quarter worth approximately $1,804,000. XTX Topco Ltd boosted its holdings in shares of Achilles Therapeutics by 239.4% in the second quarter. XTX Topco Ltd now owns 51,660 shares of the company’s stock worth $42,000 after buying an additional 36,441 shares during the last quarter. Finally, BML Capital Management LLC grew its position in Achilles Therapeutics by 555.8% during the third quarter. BML Capital Management LLC now owns 4,100,002 shares of the company’s stock valued at $4,182,000 after buying an additional 3,474,828 shares during the period. 56.38% of the stock is owned by hedge funds and other institutional investors.

Achilles Therapeutics Company Profile

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.